Recent #UPGRADES & #DOWNGRADES from S&P capital IQ: $CSGS $MT $AVT $JASO $TSL $GHDX $L $SXT $XTA $AGK $GTIV $SMP $TEN http://t.co/yOVNAdZI

$GHDX: MLV & Co cuts to Hold

Not too surprised to see $GHDX trading down today. When you sink $20M into a new biz without providing much detail, market will ding you.

Looks like $GHDX heard the message loud and clear on the Roche $ILMN bid. There's a lot of money to be made on sequencing in the practice.

$GHDX forming a new genetics subsidiary. Will "focus on integrating genetic info from the human genome into routine medical practice."

$GHDX reports tonight. We'll see what kind of margins they post this time around. Interested to see how the colon test has been selling too.

Here are all of the stocks recommended at the Harbor Investment Conference: $RNF, $RTK, $DST, $TSLA, $FIO, $GHDX #HICO

Catherine Wood: $ghdx #HICO

$GHDX said today that Oncotype DX changes 29% of treatment decisions in the stage II colon market. Meaning it costs about $10K/outcome.

@johnwelshtrades Marc Lichtenfeld pumping $GHDX in newsletter.

Prostate cancer Dx getting to be a very crowded field. $MYGN $GPRO and $GHDX all boasting about their prostate cancer diagnostics this year.

Wish $GHDX would have described the clinical utility they are going after with the prostate cancer test a little more vis-a-vis Gleason.

$GHDX CEO: One 1 in every 2 women with early stage breast cancer are getting Oncotype. Says huge room for growth, will expand sales force.

It will be very interesting to see how much value they think Oncotype Dx adds beyond a Gleason Score. Results expected by end of year. $GHDX

$GHDX launches Oncotype DX trial in prostate cancer. Aims to distinguish those who need radical prostatectomy vs active surveillance.